HCR 578: Duty of Care
HCR 578: Duty of Care
The principal investigator (PI) has the obvious Duty of Care to the study participants, though this term is not specifically present in the informed consent form. Instead, this duty is implied through several elements of the document.
First, the consent identifies that participants would be monitored through screening, follow-up visits, and safety assessments. This means the principal investigator bears the responsibility for the health and safety of the participant throughout the study (US Department of Health and Human Services). Follow-up visits regularly at 2, 4, 12, and 24 weeks after addressing the issue demonstrate dedication to continued oversight and not abandoning participants after administering treatment.
Second, the section on risks and side effects shows the PI’s responsibilities of warning participants about foreseeable harms. By reporting adverse effects such as discomfort, allergic reactions, or infection, the principal investigator is acknowledging the duty to disclose information that may enable participants to make an informed decision (Yarborough & Sharp, 2009). This openness is included in the ethical requirement of the duty of care, which is to protect participants against unforeseen or preventable dangers.
Third, the consent form contains a part that in the case of complications or injuries that may arise because of the study procedures, the investigator will cover the normal charges of treating the injuries. This goes straight to the role of PI in ensuring the participants are not left without medical care in the event of harm during the trial.
Fourth, confidentiality protections further imply a duty of care. Ensuring that the personal health information is secure and does not get into the wrong hands, the PI is committed to protecting the privacy of the participants (US Department of Health and Human Services). This is central in preserving trust, which has been promoted in the wider studies on research ethics following instances like that of Jesse Gelsinger, where a lack of openness and security of participants damaged public confidence.
Finally, the voluntary participation and withdrawal rights emphasize respect for participant autonomy. Giving the participants an option of exiting the study without any repercussions creates the illusion that the principal investigator is more concerned about their welfare than their research interests (Yarborough & Sharp, 2009). Ethical guidelines, such as those recommended by the FDA and ICH, emphasize that the rights and safety of participants should be of utmost importance compared to study results.
In a nutshell, the informed consent indicates the PI’s obligation of care by monitoring the participants, disclosure of risks, commitment to medical care, confidentiality, and respect of autonomy. Taken together, these aspects indicate that the PI has the duty to act in the best interest of participants during the study.
References
US Department of Health and Human Services. E11 (R1) addendum: clinical investigation of medicinal products in the pediatric population: guidance for industry.
Yarborough, M., & Sharp, R. R. (2009). Public trust and research a decade later: What have we learned since Jesse Gelsinger’s death? Molecular Genetics and Metabolism, 97(1), 4–5. https://doi.org/10.1016/j.ymgme.2009.02.002
HCR 578: Duty of Care
